Active Pharmaceutical Ingredient (API)

What Is an Active Pharmaceutical Ingredient (API)?

Within a finished medicine only a small proportion of the mass usually does anything therapeutic, and that fraction is generally the most expensive and most tightly controlled input in the formulation. Everything else in the tablet or the vial exists to carry, bind, preserve, stabilise or flavour, and while those materials matter to the product they carry neither the cost nor the regulatory weight.

For stock purposes the consequence is that this material is tracked far more closely than anything else in the store. It is received against a specification and a certificate of analysis, held in defined conditions with monitoring, quarantined until released by the quality function, and issued against a batch record that ties consumption to the finished output it produced. Verification therefore examines the release status alongside the quantity, because material physically present but not yet released is not available for use, and material whose retest date has passed is in the same position despite appearing entirely ordinary on the rack.

Active Pharmaceutical Ingredient (API) Under Indian Law

Position: manufacture of active ingredients requires a licence from the state licensing authority, and the site must operate to the good manufacturing practice requirements laid down by rule.

• Those requirements govern premises, plant, storage conditions and records. Batch manufacturing records, records of starting materials, analytical results and distribution records all have to be maintained and made available.
• Source: the Drugs and Cosmetics Act 1940 and the Drugs and Cosmetics Rules 1945, with good manufacturing practice at Schedule M.
• Note: enforcement rests with state drug control authorities and interpretation can vary between states. Schedule M has been substantially revised with phased application, so the applicable version should be confirmed for the site rather than assumed from an older text.

Which Sectors Use Active Pharmaceutical Ingredient (API) and Why

The term is confined to the pharmaceutical value chain and to the businesses immediately around it.

• Formulation manufacturers, for whom it is the highest-value input and the most tightly controlled line in the store.
• Bulk drug and active ingredient manufacturers, for whom it is the finished product rather than an input.
• Contract manufacturers, holding material that frequently belongs to a principal rather than to themselves.
• Specialist distributors and importers supplying formulators, subject to the same storage and documentation requirements.
• Veterinary and nutraceutical manufacturing, where equivalent concepts apply under their own regulatory frameworks.
• Outside that chain the term has no application at all, which is why a general stock auditor without sector experience is a poor fit for these sites.

How Active Pharmaceutical Ingredient (API) Works in Practice

1. Material arrives against a purchase specification, accompanied by the supplier's certificate of analysis, and is booked into a blocked status immediately.

1. Samples are drawn and tested in-house against the specification, since a supplier certificate supports the position and does not replace incoming verification.

1. The quality function releases the batch, at which point it becomes available for use. Nothing is issued before that release, however urgent the production schedule.

1. Storage follows the defined conditions with monitoring in place, and the batch identity travels with the material through every subsequent movement.

1. On issue, consumption is recorded against the batch record for the product being made, so what went in can be traced to what came out. The batch is reconciled at the end: quantity received, less issued, less samples and retention, less any destruction, against what remains.

Active Pharmaceutical Ingredient (API): A Worked Example

One batch of 60,000 tablets at a Sikkim facility, broken into its three material inputs.

The API is 2% of the weight and 77% of the value, and that ratio governs how the batch is verified. A 5% counting error on excipients moves the batch value by about Rs 22,000. The same error on the API moves it by Rs 1.64 lakh. So the API is weighed on calibrated scales, reconciled against dispensing records batch by batch, and held under separate access control, while excipients are checked far more lightly. Verification effort tracks value density rather than volume, which is why the smallest quantity on the table takes the most attention.

Common Mistakes With Active Pharmaceutical Ingredient (API)

Quantity is the least of what has to be right about this material.

• Counting it as ordinary stock without recording release status, so material still awaiting a quality decision is reported as available.
• Storing lots together without individual marking, which establishes the total while leaving the batch composition unverifiable.
• Issuing against a batch record that was never reconciled, so consumption cannot be tied to the output it produced.
• Overlooking a retest date that has passed, which leaves material in the same position as unreleased stock despite looking entirely ordinary on the rack.
• Valuing it without reference to how it was held, since a logged temperature breach can strip every rupee of worth from the costliest material in the store.
• Reconciling consumption to output in aggregate only, which hides losses a batch-by-batch comparison would expose.
• Taking a supplier certificate in place of testing on receipt where the specification calls for both.

Related Stock Audit Terms

Until it is released it sits in a blocked status, so quarantine stock is the entry to read next. Every other term in this cluster is listed in the A-Z of stock audit terms, grouped by the part of the work it belongs to.